| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveal Neoplasms | 89 | 2024 | 344 | 8.750 |
Why?
|
| Choroid Neoplasms | 76 | 2023 | 177 | 7.460 |
Why?
|
| Melanoma | 135 | 2024 | 5705 | 4.290 |
Why?
|
| Photochemotherapy | 38 | 2021 | 830 | 1.910 |
Why?
|
| Choroidal Neovascularization | 28 | 2014 | 364 | 1.880 |
Why?
|
| Porphyrins | 31 | 2014 | 352 | 1.830 |
Why?
|
| Photosensitizing Agents | 33 | 2021 | 631 | 1.800 |
Why?
|
| Ciliary Body | 15 | 2020 | 168 | 1.750 |
Why?
|
| Iris | 12 | 2020 | 231 | 1.740 |
Why?
|
| Iris Neoplasms | 5 | 2020 | 13 | 1.470 |
Why?
|
| Optic Nerve Neoplasms | 4 | 2015 | 45 | 1.440 |
Why?
|
| Optic Disk | 14 | 2015 | 422 | 1.440 |
Why?
|
| Choroid Diseases | 9 | 2018 | 63 | 1.300 |
Why?
|
| Macular Degeneration | 23 | 2022 | 1016 | 1.300 |
Why?
|
| Radiotherapy, High-Energy | 21 | 2010 | 228 | 1.250 |
Why?
|
| Choroid | 34 | 2023 | 363 | 1.210 |
Why?
|
| Nevus, Pigmented | 4 | 2015 | 221 | 1.210 |
Why?
|
| Visual Acuity | 41 | 2024 | 2714 | 1.190 |
Why?
|
| Protons | 53 | 2022 | 1112 | 1.150 |
Why?
|
| Radiation Injuries | 16 | 2018 | 1204 | 1.100 |
Why?
|
| Retinal Diseases | 23 | 2016 | 710 | 1.100 |
Why?
|
| Eye Neoplasms | 17 | 2022 | 306 | 1.060 |
Why?
|
| Retinal Detachment | 18 | 2021 | 429 | 0.980 |
Why?
|
| Eye Enucleation | 22 | 2014 | 128 | 0.970 |
Why?
|
| Fluorescein Angiography | 69 | 2021 | 1086 | 0.940 |
Why?
|
| Sturge-Weber Syndrome | 2 | 2022 | 89 | 0.870 |
Why?
|
| Iris Diseases | 3 | 2020 | 36 | 0.770 |
Why?
|
| Glaucoma, Neovascular | 3 | 2020 | 37 | 0.770 |
Why?
|
| Neovascularization, Pathologic | 19 | 2013 | 2635 | 0.710 |
Why?
|
| Melanoma, Experimental | 14 | 2004 | 559 | 0.660 |
Why?
|
| Pigmentation Disorders | 1 | 2020 | 104 | 0.650 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 223 | 0.600 |
Why?
|
| Cause of Death | 6 | 2016 | 3728 | 0.580 |
Why?
|
| Retina | 30 | 2014 | 2661 | 0.540 |
Why?
|
| Retinal Neoplasms | 3 | 2014 | 151 | 0.540 |
Why?
|
| Retinal Vein Occlusion | 5 | 2015 | 149 | 0.540 |
Why?
|
| Blindness | 4 | 2015 | 587 | 0.530 |
Why?
|
| Retinal Neovascularization | 5 | 2015 | 288 | 0.530 |
Why?
|
| Fundus Oculi | 33 | 2011 | 560 | 0.510 |
Why?
|
| Retinal Artery Occlusion | 1 | 2015 | 83 | 0.480 |
Why?
|
| Scleral Diseases | 3 | 2012 | 22 | 0.480 |
Why?
|
| Granuloma | 1 | 2017 | 329 | 0.470 |
Why?
|
| Survival Rate | 23 | 2024 | 12870 | 0.460 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2014 | 137 | 0.440 |
Why?
|
| Tomography, Optical Coherence | 7 | 2021 | 2957 | 0.430 |
Why?
|
| Retinoblastoma | 6 | 2014 | 321 | 0.430 |
Why?
|
| Vascular Endothelial Growth Factor A | 23 | 2022 | 3520 | 0.420 |
Why?
|
| Radiotherapy Dosage | 23 | 2022 | 2920 | 0.410 |
Why?
|
| Sarcoidosis | 3 | 2017 | 534 | 0.410 |
Why?
|
| Liver Neoplasms | 7 | 2018 | 4360 | 0.410 |
Why?
|
| Eye | 8 | 2012 | 713 | 0.410 |
Why?
|
| Uveitis | 8 | 2008 | 398 | 0.410 |
Why?
|
| Organometallic Compounds | 6 | 2003 | 648 | 0.410 |
Why?
|
| Macula Lutea | 10 | 1999 | 180 | 0.410 |
Why?
|
| Awards and Prizes | 1 | 2016 | 365 | 0.400 |
Why?
|
| Neoplasm Metastasis | 17 | 2024 | 4921 | 0.400 |
Why?
|
| Follow-Up Studies | 47 | 2024 | 39405 | 0.390 |
Why?
|
| Aged, 80 and over | 58 | 2024 | 59683 | 0.380 |
Why?
|
| Paraneoplastic Syndromes | 3 | 2001 | 155 | 0.380 |
Why?
|
| Retinal Vessels | 16 | 2009 | 864 | 0.380 |
Why?
|
| Endotoxins | 4 | 2008 | 520 | 0.370 |
Why?
|
| Middle Aged | 128 | 2024 | 223463 | 0.360 |
Why?
|
| Ophthalmology | 2 | 2016 | 560 | 0.350 |
Why?
|
| Capillary Permeability | 15 | 2009 | 773 | 0.340 |
Why?
|
| Integrin alpha4 | 1 | 2009 | 88 | 0.330 |
Why?
|
| Humans | 241 | 2024 | 768298 | 0.320 |
Why?
|
| Male | 157 | 2024 | 364870 | 0.320 |
Why?
|
| Optic Nerve Diseases | 5 | 2010 | 342 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 9433 | 0.320 |
Why?
|
| Aged | 104 | 2024 | 171544 | 0.310 |
Why?
|
| Female | 156 | 2024 | 397050 | 0.310 |
Why?
|
| Hemangioma | 4 | 2022 | 727 | 0.300 |
Why?
|
| Aminoimidazole Carboxamide | 3 | 2014 | 85 | 0.300 |
Why?
|
| Ribonucleotides | 3 | 2014 | 114 | 0.300 |
Why?
|
| Vitreous Body | 12 | 2006 | 400 | 0.300 |
Why?
|
| Rabbits | 27 | 2004 | 4782 | 0.280 |
Why?
|
| Adult | 104 | 2024 | 223622 | 0.280 |
Why?
|
| Cobalt Radioisotopes | 5 | 2005 | 75 | 0.280 |
Why?
|
| Integrin alpha4beta1 | 1 | 2007 | 119 | 0.270 |
Why?
|
| Brachytherapy | 6 | 2022 | 1226 | 0.260 |
Why?
|
| Laser Coagulation | 5 | 2011 | 333 | 0.260 |
Why?
|
| Phosphenes | 1 | 2006 | 41 | 0.260 |
Why?
|
| Fovea Centralis | 7 | 2015 | 126 | 0.260 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 1614 | 0.260 |
Why?
|
| Blood-Retinal Barrier | 4 | 2009 | 63 | 0.250 |
Why?
|
| Germ-Line Mutation | 5 | 2017 | 1885 | 0.250 |
Why?
|
| Retinitis | 2 | 2001 | 36 | 0.250 |
Why?
|
| Lung Neoplasms | 6 | 2020 | 13576 | 0.250 |
Why?
|
| Endothelial Growth Factors | 8 | 2003 | 674 | 0.250 |
Why?
|
| Interferon-alpha | 1 | 2009 | 910 | 0.240 |
Why?
|
| Vision Disorders | 6 | 2018 | 1093 | 0.240 |
Why?
|
| Lymphokines | 8 | 2003 | 927 | 0.240 |
Why?
|
| Oligonucleotides | 2 | 2004 | 564 | 0.230 |
Why?
|
| Cataract Extraction | 3 | 2002 | 465 | 0.230 |
Why?
|
| Sclera | 6 | 2003 | 189 | 0.230 |
Why?
|
| Macaca fascicularis | 16 | 2007 | 913 | 0.230 |
Why?
|
| Diabetic Retinopathy | 4 | 2009 | 1299 | 0.230 |
Why?
|
| Sound | 1 | 2006 | 261 | 0.220 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2018 | 309 | 0.220 |
Why?
|
| Skin Neoplasms | 11 | 2023 | 5857 | 0.220 |
Why?
|
| Calcinosis | 1 | 2012 | 1482 | 0.220 |
Why?
|
| Choroid Hemorrhage | 2 | 1997 | 6 | 0.210 |
Why?
|
| Hallucinations | 1 | 2006 | 375 | 0.210 |
Why?
|
| Ultrasonography, Doppler, Color | 3 | 2001 | 234 | 0.200 |
Why?
|
| Integrins | 1 | 2007 | 843 | 0.200 |
Why?
|
| Retrospective Studies | 27 | 2024 | 81768 | 0.200 |
Why?
|
| Intravitreal Injections | 3 | 2022 | 401 | 0.200 |
Why?
|
| Optic Neuritis | 2 | 2001 | 175 | 0.190 |
Why?
|
| Radiotherapy | 7 | 2018 | 1509 | 0.190 |
Why?
|
| Ophthalmoscopy | 9 | 2008 | 172 | 0.190 |
Why?
|
| Rose Bengal | 1 | 2002 | 115 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 7 | 1996 | 349 | 0.190 |
Why?
|
| Plant Lectins | 2 | 2000 | 103 | 0.180 |
Why?
|
| Disease Models, Animal | 24 | 2018 | 18358 | 0.180 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2015 | 462 | 0.180 |
Why?
|
| Organophosphorus Compounds | 2 | 1992 | 207 | 0.180 |
Why?
|
| Conjunctival Neoplasms | 1 | 2021 | 77 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 2911 | 0.170 |
Why?
|
| Uveal Diseases | 7 | 1988 | 45 | 0.170 |
Why?
|
| Microscopy, Acoustic | 1 | 2020 | 47 | 0.170 |
Why?
|
| Prognosis | 22 | 2024 | 30020 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 5422 | 0.170 |
Why?
|
| Indocyanine Green | 4 | 1999 | 238 | 0.160 |
Why?
|
| Ophthalmologic Surgical Procedures | 5 | 2018 | 354 | 0.160 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 13696 | 0.160 |
Why?
|
| Indoles | 3 | 2002 | 1825 | 0.160 |
Why?
|
| Sodium | 6 | 1993 | 1594 | 0.160 |
Why?
|
| Adolescent | 39 | 2021 | 89182 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2016 | 594 | 0.160 |
Why?
|
| Dose-Response Relationship, Radiation | 5 | 2014 | 881 | 0.160 |
Why?
|
| Elastic Tissue | 2 | 2008 | 66 | 0.160 |
Why?
|
| Treatment Outcome | 25 | 2024 | 65365 | 0.160 |
Why?
|
| Rats, Inbred BN | 9 | 2009 | 231 | 0.150 |
Why?
|
| Light | 5 | 2017 | 1354 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8628 | 0.150 |
Why?
|
| Amine Oxidase (Copper-Containing) | 2 | 2008 | 41 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2022 | 2060 | 0.150 |
Why?
|
| Animals | 78 | 2018 | 169322 | 0.150 |
Why?
|
| Reproductive History | 1 | 1999 | 210 | 0.150 |
Why?
|
| Time Factors | 15 | 2020 | 40267 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 11254 | 0.150 |
Why?
|
| Blood Volume | 3 | 2004 | 545 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 6541 | 0.150 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1999 | 218 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 1748 | 0.140 |
Why?
|
| Eye Color | 3 | 2000 | 35 | 0.140 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 165 | 0.140 |
Why?
|
| Laser Therapy | 13 | 2003 | 1105 | 0.140 |
Why?
|
| Lens, Crystalline | 3 | 1995 | 387 | 0.140 |
Why?
|
| Endothelium, Vascular | 8 | 2009 | 4427 | 0.140 |
Why?
|
| Vitreous Hemorrhage | 1 | 1997 | 47 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 5 | 2014 | 1705 | 0.140 |
Why?
|
| Melanoma, Amelanotic | 1 | 2016 | 19 | 0.130 |
Why?
|
| Rats | 18 | 2011 | 23833 | 0.130 |
Why?
|
| Apoptosis | 9 | 2014 | 9506 | 0.130 |
Why?
|
| Choroiditis | 1 | 1996 | 12 | 0.130 |
Why?
|
| Pigment Epithelium of Eye | 9 | 2005 | 209 | 0.130 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1997 | 332 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 9 | 2009 | 9261 | 0.130 |
Why?
|
| Visual Fields | 4 | 2000 | 1067 | 0.130 |
Why?
|
| Uveitis, Posterior | 1 | 1996 | 45 | 0.130 |
Why?
|
| Retinal Drusen | 1 | 2016 | 78 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 1174 | 0.130 |
Why?
|
| Bruch Membrane | 4 | 2011 | 65 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 1992 | 3781 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2015 | 2811 | 0.120 |
Why?
|
| Drug Carriers | 8 | 2003 | 710 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3609 | 0.120 |
Why?
|
| Serum Albumin, Bovine | 2 | 2009 | 320 | 0.120 |
Why?
|
| Scotoma | 1 | 1996 | 128 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2004 | 1133 | 0.120 |
Why?
|
| Diagnosis, Differential | 11 | 2014 | 13019 | 0.120 |
Why?
|
| Phosphotransferases (Phosphate Group Acceptor) | 1 | 2014 | 18 | 0.120 |
Why?
|
| Eye Foreign Bodies | 1 | 1994 | 51 | 0.110 |
Why?
|
| Ultrasonography | 11 | 2014 | 6001 | 0.110 |
Why?
|
| Cell Adhesion | 4 | 2009 | 3101 | 0.110 |
Why?
|
| Confidence Intervals | 3 | 2015 | 2931 | 0.110 |
Why?
|
| Leukocytes | 5 | 2009 | 2030 | 0.110 |
Why?
|
| Lipoproteins | 2 | 1997 | 880 | 0.110 |
Why?
|
| Exudates and Transudates | 6 | 2001 | 175 | 0.110 |
Why?
|
| Ischemia | 6 | 2003 | 1900 | 0.110 |
Why?
|
| Rats, Long-Evans | 3 | 2009 | 380 | 0.110 |
Why?
|
| Retinal Hemorrhage | 7 | 1997 | 98 | 0.110 |
Why?
|
| Injections | 7 | 2006 | 840 | 0.110 |
Why?
|
| Time | 1 | 2015 | 546 | 0.110 |
Why?
|
| Light Coagulation | 8 | 2011 | 72 | 0.110 |
Why?
|
| Phosphoproteins | 3 | 2017 | 2448 | 0.100 |
Why?
|
| Safety | 10 | 2005 | 1159 | 0.100 |
Why?
|
| Photography | 9 | 2006 | 537 | 0.100 |
Why?
|
| Retinitis Pigmentosa | 2 | 1987 | 395 | 0.100 |
Why?
|
| Liposomes | 7 | 1999 | 792 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 1993 | 259 | 0.100 |
Why?
|
| Neoplasm Transplantation | 8 | 2013 | 2017 | 0.100 |
Why?
|
| Leukostasis | 2 | 2009 | 23 | 0.100 |
Why?
|
| Transcription Factors | 4 | 2021 | 12166 | 0.100 |
Why?
|
| Cell Proliferation | 7 | 2021 | 10464 | 0.100 |
Why?
|
| Dysprosium | 1 | 1992 | 24 | 0.100 |
Why?
|
| Aqueous Humor | 2 | 2000 | 152 | 0.100 |
Why?
|
| Cataract | 4 | 1995 | 837 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 6856 | 0.100 |
Why?
|
| Fluorescein-5-isothiocyanate | 3 | 2005 | 222 | 0.100 |
Why?
|
| Prospective Studies | 15 | 2021 | 54921 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2012 | 103 | 0.100 |
Why?
|
| Eye Diseases | 6 | 2004 | 657 | 0.100 |
Why?
|
| Young Adult | 9 | 2024 | 60048 | 0.100 |
Why?
|
| Retinal Vein | 4 | 1998 | 47 | 0.100 |
Why?
|
| Up-Regulation | 4 | 2009 | 4137 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 2 | 2008 | 1614 | 0.100 |
Why?
|
| Neuroglia | 1 | 2017 | 960 | 0.090 |
Why?
|
| Blotting, Western | 6 | 2014 | 5033 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 749 | 0.090 |
Why?
|
| Edetic Acid | 1 | 1992 | 278 | 0.090 |
Why?
|
| Optic Nerve | 3 | 2006 | 571 | 0.090 |
Why?
|
| Risk Factors | 26 | 2024 | 74954 | 0.090 |
Why?
|
| Ultraviolet Rays | 3 | 2000 | 1100 | 0.090 |
Why?
|
| Eye Proteins | 2 | 2007 | 628 | 0.090 |
Why?
|
| Contraceptives, Oral | 1 | 1993 | 562 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2889 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2011 | 103 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 504 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1111 | 0.090 |
Why?
|
| Hyperthermia, Induced | 5 | 2004 | 417 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2009 | 3811 | 0.090 |
Why?
|
| Skull Base Neoplasms | 1 | 2014 | 281 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2016 | 1575 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 1999 | 1679 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 5 | 2011 | 610 | 0.090 |
Why?
|
| Chelating Agents | 1 | 1992 | 385 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2015 | 2281 | 0.090 |
Why?
|
| Caspase 3 | 3 | 2007 | 731 | 0.090 |
Why?
|
| Classification | 1 | 1990 | 128 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 8 | 2014 | 6132 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 2094 | 0.080 |
Why?
|
| Capillary Leak Syndrome | 1 | 2009 | 34 | 0.080 |
Why?
|
| Adenylate Kinase | 1 | 2010 | 102 | 0.080 |
Why?
|
| Antibodies | 1 | 2018 | 2425 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 9508 | 0.080 |
Why?
|
| Age Distribution | 1 | 2015 | 2877 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 3631 | 0.080 |
Why?
|
| Retinal Degeneration | 3 | 2007 | 414 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2018 | 4740 | 0.080 |
Why?
|
| Angiography | 2 | 1994 | 1597 | 0.080 |
Why?
|
| Uveitis, Anterior | 2 | 2007 | 101 | 0.080 |
Why?
|
| Fluorescein | 4 | 2006 | 175 | 0.080 |
Why?
|
| Skin | 3 | 2012 | 4499 | 0.080 |
Why?
|
| United States | 8 | 2019 | 73144 | 0.080 |
Why?
|
| Antibodies, Blocking | 1 | 2009 | 250 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 525 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2024 | 8730 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2016 | 2771 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2009 | 1122 | 0.080 |
Why?
|
| Photoreceptor Cells | 2 | 2008 | 234 | 0.080 |
Why?
|
| Vasculitis | 2 | 1986 | 524 | 0.080 |
Why?
|
| Forecasting | 1 | 2017 | 2948 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 2066 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 2741 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2014 | 3585 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2015 | 10117 | 0.070 |
Why?
|
| Dextrans | 2 | 2000 | 574 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 8 | 2003 | 750 | 0.070 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2008 | 149 | 0.070 |
Why?
|
| Collagen Type XVIII | 1 | 2007 | 52 | 0.070 |
Why?
|
| Tissue Distribution | 4 | 2002 | 2298 | 0.070 |
Why?
|
| Combined Modality Therapy | 7 | 2009 | 8562 | 0.070 |
Why?
|
| Caspase 9 | 1 | 2007 | 184 | 0.070 |
Why?
|
| Child | 14 | 2022 | 80894 | 0.070 |
Why?
|
| Fatal Outcome | 4 | 2014 | 1837 | 0.070 |
Why?
|
| Radioisotope Teletherapy | 1 | 2006 | 15 | 0.070 |
Why?
|
| Eye Hemorrhage | 1 | 1987 | 19 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 16027 | 0.070 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 1987 | 29 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2009 | 3553 | 0.070 |
Why?
|
| Endostatins | 1 | 2007 | 168 | 0.070 |
Why?
|
| Drug Delivery Systems | 4 | 2004 | 2236 | 0.070 |
Why?
|
| Metformin | 1 | 2014 | 911 | 0.070 |
Why?
|
| Benzoquinones | 1 | 2007 | 198 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 13 | 2011 | 22355 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 4 | 2007 | 2636 | 0.070 |
Why?
|
| Genetic Testing | 1 | 1999 | 3587 | 0.070 |
Why?
|
| Electroretinography | 3 | 2002 | 524 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 5 | 1992 | 1629 | 0.070 |
Why?
|
| Case-Control Studies | 11 | 2017 | 22292 | 0.060 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2008 | 353 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2009 | 1794 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 515 | 0.060 |
Why?
|
| Chlamydophila Infections | 1 | 2005 | 23 | 0.060 |
Why?
|
| Recombinant Proteins | 5 | 2009 | 6512 | 0.060 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2007 | 203 | 0.060 |
Why?
|
| Uvea | 1 | 2005 | 31 | 0.060 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2005 | 53 | 0.060 |
Why?
|
| Polyarteritis Nodosa | 1 | 1986 | 70 | 0.060 |
Why?
|
| Lactams, Macrocyclic | 1 | 2007 | 319 | 0.060 |
Why?
|
| Endothelium | 1 | 2008 | 768 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2005 | 57 | 0.060 |
Why?
|
| Glaucoma | 6 | 2006 | 1194 | 0.060 |
Why?
|
| Regression Analysis | 7 | 1999 | 6350 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2001 | 1375 | 0.060 |
Why?
|
| Boric Acids | 1 | 2004 | 5 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2014 | 36849 | 0.060 |
Why?
|
| Thimerosal | 1 | 2004 | 15 | 0.060 |
Why?
|
| Oxides | 2 | 2004 | 403 | 0.060 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2007 | 692 | 0.060 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2007 | 423 | 0.060 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2004 | 9 | 0.060 |
Why?
|
| Glucocorticoids | 2 | 2008 | 2168 | 0.060 |
Why?
|
| Mice | 19 | 2018 | 82004 | 0.060 |
Why?
|
| Genome, Human | 1 | 2017 | 4450 | 0.060 |
Why?
|
| Monosomy | 1 | 2024 | 52 | 0.060 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2006 | 251 | 0.060 |
Why?
|
| Anterior Chamber | 3 | 1992 | 194 | 0.060 |
Why?
|
| Ovarian Neoplasms | 2 | 1999 | 4908 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2002 | 2664 | 0.050 |
Why?
|
| Visual Field Tests | 1 | 2006 | 415 | 0.050 |
Why?
|
| Aptamers, Nucleotide | 1 | 2004 | 162 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2009 | 2487 | 0.050 |
Why?
|
| Disease Progression | 3 | 2017 | 13646 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 9618 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2004 | 293 | 0.050 |
Why?
|
| Lasers | 4 | 2011 | 952 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2018 | 2673 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2015 | 9681 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2008 | 423 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1987 | 746 | 0.050 |
Why?
|
| Proportional Hazards Models | 8 | 2010 | 12557 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 5802 | 0.050 |
Why?
|
| Postoperative Complications | 4 | 2002 | 15854 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2008 | 1186 | 0.050 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 312 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2022 | 664 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 1992 | 1817 | 0.050 |
Why?
|
| Chlorophyllides | 1 | 2002 | 54 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2017 | 9380 | 0.050 |
Why?
|
| Iodine Radioisotopes | 2 | 2016 | 1035 | 0.050 |
Why?
|
| Eye Infections, Bacterial | 1 | 2005 | 240 | 0.050 |
Why?
|
| E-Selectin | 1 | 2004 | 578 | 0.050 |
Why?
|
| Injections, Intravenous | 5 | 2000 | 1378 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 17132 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 84 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 550 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2015 | 24316 | 0.050 |
Why?
|
| Deferoxamine | 1 | 2002 | 155 | 0.050 |
Why?
|
| Polyglycolic Acid | 1 | 2003 | 408 | 0.050 |
Why?
|
| Oligopeptides | 2 | 2004 | 1194 | 0.050 |
Why?
|
| Acoustic Stimulation | 1 | 2006 | 1253 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 18047 | 0.050 |
Why?
|
| Eye Injuries | 2 | 1981 | 227 | 0.050 |
Why?
|
| Interleukin-1beta | 2 | 2023 | 1020 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2015 | 41791 | 0.050 |
Why?
|
| Metalloporphyrins | 1 | 2000 | 42 | 0.050 |
Why?
|
| Iron Chelating Agents | 1 | 2002 | 141 | 0.050 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2001 | 238 | 0.040 |
Why?
|
| Quinolines | 1 | 2006 | 768 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 4357 | 0.040 |
Why?
|
| Pedigree | 5 | 2012 | 4545 | 0.040 |
Why?
|
| Plasminogen | 1 | 2000 | 144 | 0.040 |
Why?
|
| Serpins | 1 | 2002 | 245 | 0.040 |
Why?
|
| Scleral Buckling | 3 | 1996 | 95 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2008 | 1965 | 0.040 |
Why?
|
| Angioid Streaks | 1 | 2000 | 14 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 2 | 1991 | 561 | 0.040 |
Why?
|
| Carrier Proteins | 2 | 2008 | 4940 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2004 | 12457 | 0.040 |
Why?
|
| Cell Cycle | 3 | 2014 | 2934 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2017 | 691 | 0.040 |
Why?
|
| Histoplasmosis | 1 | 2000 | 63 | 0.040 |
Why?
|
| Ophthalmoscopes | 1 | 1979 | 21 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2022 | 3728 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2015 | 8072 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2002 | 993 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2000 | 158 | 0.040 |
Why?
|
| Nose Neoplasms | 2 | 1999 | 250 | 0.040 |
Why?
|
| Lipoproteins, LDL | 4 | 1996 | 643 | 0.040 |
Why?
|
| Particle Accelerators | 5 | 1990 | 173 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2002 | 564 | 0.040 |
Why?
|
| Eye Infections, Fungal | 1 | 2000 | 99 | 0.040 |
Why?
|
| Lectins | 2 | 2000 | 490 | 0.040 |
Why?
|
| Angiomatosis | 1 | 1978 | 46 | 0.040 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 1999 | 58 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 1979 | 111 | 0.040 |
Why?
|
| Refraction, Ocular | 1 | 1999 | 186 | 0.040 |
Why?
|
| Retreatment | 3 | 2010 | 600 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 4 | 2015 | 313 | 0.040 |
Why?
|
| Recurrence | 3 | 2001 | 8501 | 0.040 |
Why?
|
| Drug Combinations | 3 | 2004 | 2078 | 0.040 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2017 | 39 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 540 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2017 | 31 | 0.040 |
Why?
|
| Neoplasms | 7 | 2017 | 22389 | 0.040 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2004 | 742 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2003 | 1140 | 0.040 |
Why?
|
| Alu Elements | 1 | 2018 | 116 | 0.040 |
Why?
|
| Fibrosis | 2 | 1996 | 2076 | 0.040 |
Why?
|
| Retinal Perforations | 1 | 1999 | 138 | 0.040 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 91 | 0.040 |
Why?
|
| Myopia | 1 | 2000 | 252 | 0.040 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1978 | 154 | 0.040 |
Why?
|
| Iron | 2 | 2004 | 1815 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 1997 | 9063 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 2008 | 413 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2277 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2010 | 20766 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 1999 | 311 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 6084 | 0.030 |
Why?
|
| Cell Survival | 4 | 2014 | 5792 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 221 | 0.030 |
Why?
|
| Microspheres | 3 | 2008 | 789 | 0.030 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1979 | 264 | 0.030 |
Why?
|
| Ocular Hypertension | 1 | 2018 | 211 | 0.030 |
Why?
|
| Technology, Radiologic | 3 | 1988 | 160 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1658 | 0.030 |
Why?
|
| Edema | 2 | 1996 | 766 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 347 | 0.030 |
Why?
|
| Cyclosporine | 2 | 1996 | 779 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 1997 | 144 | 0.030 |
Why?
|
| Ribonuclease III | 1 | 2018 | 270 | 0.030 |
Why?
|
| Radiography | 2 | 2004 | 6993 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 1664 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2018 | 1065 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 945 | 0.030 |
Why?
|
| Eye Diseases, Hereditary | 1 | 1997 | 122 | 0.030 |
Why?
|
| Syndrome | 3 | 2002 | 3275 | 0.030 |
Why?
|
| Hyperoxia | 1 | 1997 | 261 | 0.030 |
Why?
|
| Biopsy | 3 | 2013 | 6808 | 0.030 |
Why?
|
| Polymers | 1 | 2003 | 1630 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2004 | 1088 | 0.030 |
Why?
|
| Aging | 6 | 1994 | 8764 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2013 | 3630 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 1999 | 2226 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2014 | 5898 | 0.030 |
Why?
|
| Diagnostic Errors | 2 | 1997 | 1280 | 0.030 |
Why?
|
| Gene Expression | 3 | 2008 | 7595 | 0.030 |
Why?
|
| Vitrectomy | 2 | 1996 | 392 | 0.030 |
Why?
|
| Cryotherapy | 1 | 1996 | 160 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2018 | 384 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 10776 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1997 | 563 | 0.030 |
Why?
|
| Sex Factors | 5 | 1999 | 10656 | 0.030 |
Why?
|
| Hematoporphyrin Photoradiation | 1 | 1994 | 17 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2000 | 1973 | 0.030 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1981 | 809 | 0.030 |
Why?
|
| Mutation | 3 | 2017 | 30230 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 1703 | 0.030 |
Why?
|
| Azathioprine | 1 | 1996 | 354 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2008 | 12801 | 0.030 |
Why?
|
| Chemokine CCL2 | 2 | 2008 | 606 | 0.030 |
Why?
|
| Cyclotrons | 1 | 1993 | 30 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 1995 | 320 | 0.030 |
Why?
|
| Massachusetts | 4 | 1999 | 8902 | 0.030 |
Why?
|
| Interleukin-8 | 2 | 2008 | 704 | 0.030 |
Why?
|
| Aneurysm | 1 | 1997 | 343 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2014 | 42654 | 0.030 |
Why?
|
| Microcirculation | 2 | 1997 | 1282 | 0.030 |
Why?
|
| Macrophages | 4 | 2011 | 5796 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2010 | 8326 | 0.030 |
Why?
|
| Models, Animal | 3 | 2004 | 2124 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 1078 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 2006 | 2559 | 0.020 |
Why?
|
| Ferrosoferric Oxide | 2 | 2004 | 349 | 0.020 |
Why?
|
| Postal Service | 1 | 1992 | 96 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 1995 | 940 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1992 | 161 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 997 | 0.020 |
Why?
|
| Models, Structural | 1 | 1992 | 340 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2012 | 148 | 0.020 |
Why?
|
| S Phase | 1 | 2013 | 423 | 0.020 |
Why?
|
| Haplorhini | 3 | 1985 | 524 | 0.020 |
Why?
|
| Zinc | 1 | 1995 | 677 | 0.020 |
Why?
|
| Permeability | 2 | 2006 | 725 | 0.020 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 43 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 2000 | 4570 | 0.020 |
Why?
|
| Boston | 3 | 2017 | 9371 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3252 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 1643 | 0.020 |
Why?
|
| Prednisone | 1 | 1996 | 1568 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 598 | 0.020 |
Why?
|
| Methods | 2 | 1985 | 1067 | 0.020 |
Why?
|
| Rhodamines | 1 | 2011 | 178 | 0.020 |
Why?
|
| Pregnancy | 4 | 2016 | 30198 | 0.020 |
Why?
|
| Cyclins | 1 | 2013 | 606 | 0.020 |
Why?
|
| Skull Neoplasms | 3 | 1990 | 173 | 0.020 |
Why?
|
| Phosphorus | 2 | 1989 | 336 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 1995 | 20224 | 0.020 |
Why?
|
| Mice, Knockout | 4 | 2008 | 14481 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1628 | 0.020 |
Why?
|
| Diffusion | 1 | 1992 | 818 | 0.020 |
Why?
|
| Biotinylation | 1 | 2009 | 185 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2016 | 1277 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1997 | 1813 | 0.020 |
Why?
|
| Cell Count | 2 | 2006 | 1833 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 1993 | 877 | 0.020 |
Why?
|
| Mesocricetus | 2 | 1986 | 256 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1992 | 569 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2011 | 856 | 0.020 |
Why?
|
| Evans Blue | 1 | 2008 | 42 | 0.020 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2008 | 48 | 0.020 |
Why?
|
| Tantalum | 1 | 1988 | 54 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1997 | 2207 | 0.020 |
Why?
|
| Microscopy, Confocal | 2 | 2005 | 1972 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2000 | 5151 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2008 | 316 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2012 | 1090 | 0.020 |
Why?
|
| Aprotinin | 1 | 2008 | 94 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1989 | 642 | 0.020 |
Why?
|
| Cricetinae | 3 | 1986 | 2423 | 0.020 |
Why?
|
| Signal Transduction | 4 | 2017 | 23629 | 0.020 |
Why?
|
| Registries | 1 | 2024 | 8378 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 1995 | 969 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 2884 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4286 | 0.020 |
Why?
|
| Molecular Weight | 2 | 2000 | 2172 | 0.020 |
Why?
|
| Pichia | 1 | 2007 | 49 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 874 | 0.020 |
Why?
|
| Proteins | 1 | 2002 | 6006 | 0.020 |
Why?
|
| Cystadenocarcinoma | 1 | 1987 | 54 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2008 | 216 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2007 | 235 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 2487 | 0.020 |
Why?
|
| Tonometry, Ocular | 2 | 2006 | 238 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2007 | 126 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2007 | 262 | 0.020 |
Why?
|
| Retinal Vasculitis | 1 | 2007 | 46 | 0.020 |
Why?
|
| Oncogenes | 1 | 2012 | 1234 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 3722 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 1987 | 156 | 0.020 |
Why?
|
| Hand | 1 | 1992 | 912 | 0.020 |
Why?
|
| Remission Induction | 2 | 1989 | 2407 | 0.020 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2008 | 174 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2009 | 14783 | 0.020 |
Why?
|
| Elastin | 1 | 2008 | 299 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 1350 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1986 | 47 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2008 | 1165 | 0.020 |
Why?
|
| Fiber Optic Technology | 2 | 1979 | 291 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3616 | 0.020 |
Why?
|
| Brain | 2 | 2006 | 27452 | 0.020 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 1889 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 2267 | 0.020 |
Why?
|
| Contrast Media | 3 | 2004 | 5337 | 0.020 |
Why?
|
| Observer Variation | 1 | 1992 | 2623 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 1135 | 0.020 |
Why?
|
| Helium | 1 | 1986 | 119 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2068 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 393 | 0.020 |
Why?
|
| P-Selectin | 1 | 2008 | 599 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 1986 | 153 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 6319 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2006 | 624 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 1727 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1989 | 1081 | 0.020 |
Why?
|
| Cryosurgery | 2 | 1991 | 477 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 1997 | 1553 | 0.020 |
Why?
|
| Incidence | 4 | 1998 | 21544 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4526 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1991 | 1196 | 0.010 |
Why?
|
| Cells, Cultured | 4 | 2005 | 19019 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1986 | 208 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2008 | 1647 | 0.010 |
Why?
|
| Lipids | 1 | 1995 | 3344 | 0.010 |
Why?
|
| Intraocular Pressure | 2 | 2006 | 1304 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4774 | 0.010 |
Why?
|
| Cell Division | 2 | 2003 | 4478 | 0.010 |
Why?
|
| Membranes | 1 | 1984 | 164 | 0.010 |
Why?
|
| Statistics as Topic | 2 | 1988 | 2363 | 0.010 |
Why?
|
| Orbital Neoplasms | 1 | 2006 | 223 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1997 | 4785 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 4120 | 0.010 |
Why?
|
| Chordoma | 3 | 1990 | 349 | 0.010 |
Why?
|
| RNA | 2 | 2008 | 2726 | 0.010 |
Why?
|
| Cell Line | 1 | 2018 | 15593 | 0.010 |
Why?
|
| DNA Primers | 1 | 2008 | 2823 | 0.010 |
Why?
|
| Remission, Spontaneous | 3 | 1999 | 385 | 0.010 |
Why?
|
| Lenses, Intraocular | 1 | 1985 | 141 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 13038 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 623 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1996 | 4209 | 0.010 |
Why?
|
| Prevalence | 3 | 1999 | 15868 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 2003 | 337 | 0.010 |
Why?
|
| Epithelium | 1 | 1987 | 1609 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 549 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1999 | 9197 | 0.010 |
Why?
|
| Ovary | 1 | 1987 | 960 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 424 | 0.010 |
Why?
|
| Electrooculography | 1 | 2002 | 113 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1997 | 3199 | 0.010 |
Why?
|
| Patient Selection | 1 | 2014 | 4265 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1993 | 5311 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 564 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 2215 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 1339 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1990 | 6238 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 923 | 0.010 |
Why?
|
| Smoking | 3 | 1994 | 9109 | 0.010 |
Why?
|
| Angiostatins | 1 | 2000 | 64 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4584 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 11117 | 0.010 |
Why?
|
| Optic Atrophy | 1 | 1981 | 79 | 0.010 |
Why?
|
| Color | 2 | 1979 | 297 | 0.010 |
Why?
|
| Testis | 1 | 1984 | 783 | 0.010 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2000 | 49 | 0.010 |
Why?
|
| Energy Transfer | 3 | 1985 | 109 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1997 | 4301 | 0.010 |
Why?
|
| Bone Neoplasms | 2 | 1991 | 2565 | 0.010 |
Why?
|
| Coumarins | 1 | 2000 | 119 | 0.010 |
Why?
|
| Aotus trivirgatus | 1 | 1979 | 36 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2005 | 1479 | 0.010 |
Why?
|
| Retinal Ganglion Cells | 1 | 2006 | 811 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2007 | 7885 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1982 | 410 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2016 | 3431 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 841 | 0.010 |
Why?
|
| Body Temperature | 1 | 2003 | 781 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 1943 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1981 | 326 | 0.010 |
Why?
|
| Computers | 1 | 1982 | 592 | 0.010 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1979 | 88 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 1891 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1985 | 1479 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2000 | 252 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 1967 | 0.010 |
Why?
|
| Talc | 1 | 1979 | 48 | 0.010 |
Why?
|
| Random Allocation | 2 | 1996 | 2397 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2461 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1704 | 0.010 |
Why?
|
| Calcium | 1 | 1992 | 5794 | 0.010 |
Why?
|
| Gadolinium | 1 | 2003 | 965 | 0.010 |
Why?
|
| Sclerostomy | 1 | 1998 | 16 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 1732 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2011 | 3587 | 0.010 |
Why?
|
| Aphakia, Postcataract | 1 | 1978 | 52 | 0.010 |
Why?
|
| Beclomethasone | 1 | 1997 | 38 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2000 | 694 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1997 | 114 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 2695 | 0.010 |
Why?
|
| Nuclear Energy | 1 | 1977 | 15 | 0.010 |
Why?
|
| Fluorophotometry | 1 | 1997 | 40 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2007 | 3663 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 880 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2014 | 26410 | 0.010 |
Why?
|
| Capillaries | 1 | 2000 | 756 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 3108 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 16716 | 0.010 |
Why?
|
| Canada | 1 | 2003 | 2139 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 12421 | 0.010 |
Why?
|
| Cholesterol | 1 | 2006 | 2912 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3712 | 0.010 |
Why?
|
| New England | 2 | 1990 | 1058 | 0.010 |
Why?
|
| Triamcinolone Acetonide | 1 | 1997 | 105 | 0.010 |
Why?
|
| Bronchitis | 1 | 1997 | 196 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1997 | 151 | 0.010 |
Why?
|
| Actuarial Analysis | 2 | 1988 | 372 | 0.010 |
Why?
|
| Peroxidase | 1 | 2000 | 609 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 326 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 26373 | 0.010 |
Why?
|
| Albuterol | 1 | 1997 | 211 | 0.010 |
Why?
|
| Rectal Neoplasms | 3 | 1985 | 1185 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1985 | 2257 | 0.010 |
Why?
|
| Diet | 1 | 1994 | 8097 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2000 | 1760 | 0.010 |
Why?
|
| Infant | 3 | 2014 | 36512 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 1371 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 5214 | 0.010 |
Why?
|
| Trabecular Meshwork | 1 | 1996 | 101 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1996 | 287 | 0.010 |
Why?
|
| Androstadienes | 1 | 1997 | 348 | 0.010 |
Why?
|
| Embolism | 1 | 1979 | 401 | 0.010 |
Why?
|
| Methylphenidate | 1 | 1979 | 491 | 0.010 |
Why?
|
| Spinal Neoplasms | 2 | 1982 | 716 | 0.010 |
Why?
|
| Chondrosarcoma | 2 | 1990 | 306 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 3827 | 0.010 |
Why?
|
| Pregnancy Proteins | 1 | 1996 | 223 | 0.010 |
Why?
|
| Aluminum | 1 | 1995 | 150 | 0.010 |
Why?
|
| Epinephrine | 1 | 1978 | 795 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1984 | 1885 | 0.010 |
Why?
|
| Hemangiosarcoma | 1 | 1977 | 216 | 0.010 |
Why?
|
| Factor VIII | 1 | 1996 | 349 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1997 | 1169 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1982 | 2247 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 1977 | 266 | 0.010 |
Why?
|
| Nucleotides | 1 | 1996 | 455 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 1408 | 0.010 |
Why?
|
| Monocytes | 1 | 2003 | 2594 | 0.010 |
Why?
|
| Age Factors | 3 | 1988 | 18472 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 3541 | 0.010 |
Why?
|
| Data Collection | 2 | 1994 | 3324 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1996 | 710 | 0.010 |
Why?
|
| Anus Neoplasms | 1 | 1977 | 337 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1994 | 361 | 0.010 |
Why?
|
| Urticaria | 1 | 1994 | 151 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1997 | 1866 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1064 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1997 | 949 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 2646 | 0.010 |
Why?
|
| Vitamin A | 1 | 1994 | 611 | 0.010 |
Why?
|
| Carotenoids | 1 | 1994 | 621 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 925 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 10377 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 658 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1979 | 1161 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1998 | 1322 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 1882 | 0.010 |
Why?
|
| Syncope | 1 | 1994 | 430 | 0.010 |
Why?
|
| Amino Acids | 1 | 1996 | 1716 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1977 | 982 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 2 | 1991 | 2708 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1991 | 158 | 0.010 |
Why?
|
| Vitamin E | 1 | 1994 | 874 | 0.010 |
Why?
|
| Radiation | 1 | 1990 | 49 | 0.010 |
Why?
|
| Rhinitis | 1 | 1997 | 751 | 0.010 |
Why?
|
| Physical Phenomena | 1 | 1989 | 48 | 0.010 |
Why?
|
| Altitude | 1 | 1990 | 164 | 0.010 |
Why?
|
| Compliance | 1 | 1989 | 100 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1992 | 1152 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1995 | 1820 | 0.000 |
Why?
|
| Hamartoma | 1 | 1991 | 236 | 0.000 |
Why?
|
| Selection Bias | 1 | 1990 | 360 | 0.000 |
Why?
|
| Physics | 1 | 1989 | 92 | 0.000 |
Why?
|
| Video Recording | 1 | 1994 | 974 | 0.000 |
Why?
|
| Sunlight | 1 | 1990 | 337 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1994 | 1232 | 0.000 |
Why?
|
| Anemia, Sickle Cell | 1 | 1977 | 1065 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1988 | 194 | 0.000 |
Why?
|
| Quality Control | 1 | 1991 | 833 | 0.000 |
Why?
|
| Necrosis | 1 | 1992 | 1619 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1989 | 4069 | 0.000 |
Why?
|
| Glycogen | 1 | 1988 | 252 | 0.000 |
Why?
|
| Eating | 1 | 1994 | 1541 | 0.000 |
Why?
|
| Triglycerides | 1 | 1995 | 2465 | 0.000 |
Why?
|
| Radio Waves | 1 | 1989 | 254 | 0.000 |
Why?
|
| Pigmentation | 1 | 1988 | 143 | 0.000 |
Why?
|
| Equipment Safety | 1 | 1988 | 250 | 0.000 |
Why?
|
| Mitosis | 1 | 1992 | 1190 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 21163 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1997 | 4031 | 0.000 |
Why?
|
| Personality | 1 | 1990 | 560 | 0.000 |
Why?
|
| Body Fluids | 1 | 1988 | 321 | 0.000 |
Why?
|
| Antioxidants | 1 | 1994 | 1673 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 5496 | 0.000 |
Why?
|
| Models, Biological | 1 | 2003 | 9494 | 0.000 |
Why?
|
| Magnetics | 1 | 1989 | 599 | 0.000 |
Why?
|
| Cholesterol, LDL | 1 | 1995 | 2398 | 0.000 |
Why?
|
| Oxygen | 1 | 1997 | 4273 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1988 | 573 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 10266 | 0.000 |
Why?
|
| Glycosaminoglycans | 1 | 1988 | 611 | 0.000 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1989 | 330 | 0.000 |
Why?
|
| Lung | 1 | 1984 | 10087 | 0.000 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1989 | 562 | 0.000 |
Why?
|
| Ultrasonic Therapy | 1 | 1985 | 217 | 0.000 |
Why?
|
| Inflammation | 1 | 2003 | 10863 | 0.000 |
Why?
|
| Probability | 1 | 1988 | 2482 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1984 | 915 | 0.000 |
Why?
|
| Interviews as Topic | 1 | 1990 | 2740 | 0.000 |
Why?
|
| Arteriovenous Malformations | 1 | 1985 | 396 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1985 | 263 | 0.000 |
Why?
|
| Substance-Related Disorders | 1 | 1979 | 4429 | 0.000 |
Why?
|
| Vision, Ocular | 1 | 1985 | 458 | 0.000 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1985 | 335 | 0.000 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1984 | 506 | 0.000 |
Why?
|
| Research | 1 | 1990 | 1981 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1989 | 2887 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1985 | 1830 | 0.000 |
Why?
|
| Sarcoma | 2 | 1982 | 1806 | 0.000 |
Why?
|
| Equipment Design | 1 | 1988 | 3529 | 0.000 |
Why?
|
| Logistic Models | 1 | 1994 | 13323 | 0.000 |
Why?
|
| Paget Disease, Extramammary | 1 | 1980 | 51 | 0.000 |
Why?
|
| Radiobiology | 1 | 1980 | 90 | 0.000 |
Why?
|
| Weight Lifting | 1 | 1980 | 130 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1977 | 6404 | 0.000 |
Why?
|
| Asthma | 1 | 1997 | 6281 | 0.000 |
Why?
|
| Hypertension | 1 | 1998 | 8615 | 0.000 |
Why?
|
| Radiation Tolerance | 1 | 1980 | 478 | 0.000 |
Why?
|
| Mouth Neoplasms | 1 | 1982 | 597 | 0.000 |
Why?
|
| Argon | 1 | 1977 | 36 | 0.000 |
Why?
|
| Physical Exertion | 1 | 1980 | 669 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1989 | 3579 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 12092 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1971 | 6430 | 0.000 |
Why?
|
| Prostatic Neoplasms | 3 | 1985 | 11220 | 0.000 |
Why?
|
| Color Perception Tests | 1 | 1974 | 12 | 0.000 |
Why?
|
| Serous Membrane | 1 | 1974 | 23 | 0.000 |
Why?
|
| Risk | 1 | 1986 | 9635 | 0.000 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1982 | 1166 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1990 | 15455 | 0.000 |
Why?
|
| Nerve Fibers | 1 | 1977 | 709 | 0.000 |
Why?
|
| Posture | 1 | 1977 | 956 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1971 | 5890 | 0.000 |
Why?
|
| Blood Vessels | 1 | 1978 | 1110 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 1985 | 2923 | 0.000 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1982 | 2044 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 15652 | 0.000 |
Why?
|
| Glioma | 1 | 1985 | 3526 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1985 | 8051 | 0.000 |
Why?
|
| Cicatrix | 1 | 1974 | 799 | 0.000 |
Why?
|
| Anesthesia | 1 | 1977 | 1596 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1971 | 3440 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1971 | 8541 | 0.000 |
Why?
|